Atorvastatin Reduces Incidence of Heart Attacks, Strokes, in Patients with Diabetes

OCTOBER 01, 2004
Susan Farley

The cholesterol-lowering drug atorvastatin (Lipitor) offers significant benefits guarding against heart attacks and strokes among patients with diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) is the largest study of statin use in patients with diabetes, involving more than 2800 patients with type 2 diabetes, no history of heart disease, and relatively low levels of cholesterol.

Among those patients taking atorvastatin, there was a 37% reduction in major cardiovascular events, and 48% fewer patients taking atorvastatin experienced strokes, compared with those taking placebo. In fact, atorvastatin proved so effective that the study was stopped 2 years early. This was the second time a study of atorvastatin was stopped early because of significant cardiovascular benefits. The number of cases of type 2 diabetes is increasing at an epidemic level, which researchers attribute to genetics, obesity, and lack of exercise.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.